Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTcP vaccine
- Development stage
- Preclinical
- Lead developer
- AIM Vaccine Co.
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DTcP vaccine is a combination vaccine candidate being developed by AIM Honesty for the prevention of diphtheria, tetanus, and pertussis. Currently in the preclinical stage, the vaccine formulation consists of diphtheria and tetanus toxoids combined with whole-cell pertussis (cellular) antigens. Unlike acellular pertussis vaccines, this cellular approach utilizes inactivated whole *Bordetella pertussis* bacteria to stimulate a robust and broad immune response. The vaccine is designed to induce active immunity against the toxins produced by *Corynebacterium diphtheriae* and *Clostridium tetani*, as well as the *Bordetella pertussis* pathogen itself.
- Other names
- Diphtheria, Tetanus, and cellular Pertussis vaccinediphtheria + tetanus + cellular pertussis vaccine
02
Targets
TT (Tetanus toxoid)
Beyond the preview
Go deeper on DTcP vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTcP vaccine.